USAResearch and clinical trials
Experimental sevasemten in Becker muscular dystrophy: well tolerated over 2 years in 12 adults
In the USA, 12 adults with Becker muscular dystrophy took sevasemten, an experimental drug, for 24 months.
Neuromuscular diseases
An inherited muscle disease. The muscles weaken and waste away over time. It mostly affects boys and men. It progresses more slowly than the Duchenne type.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
This page is translated from the Turkish original.
This disease is followed through the “Neuromuscular diseases” group.
The disease is caused by a change in the DMD gene. This gene makes a protein called dystrophin, which protects the muscle fibers. In the Becker type, there is too little of this protein or it does not work fully. As a result, the skeletal muscles and the heart muscle are damaged over time.
Symptoms often begin between the ages of 5 and 15, but they can also appear later. The course varies from person to person.
The doctor examines the muscles and nerves. CK, a muscle enzyme, is measured in the blood. The diagnosis is confirmed with a genetic test that looks at the DMD gene. If needed, a muscle biopsy, EMG and heart tests are done.
There is not yet a treatment that cures the disease; new treatments are being researched. Care aims to control symptoms and protect quality of life. Staying active is recommended; long periods without movement can weaken the muscles. Physiotherapy helps maintain muscle strength. Mobility aids and a wheelchair make getting around easier. The heart is checked regularly; if needed, devices such as a pacemaker are fitted. Some doctors may recommend steroid treatment. The doctor who follows the disease decides which treatment is suitable.
The disease is passed on through X-linked recessive inheritance. This is why mostly boys are affected. An affected boy usually inherits the gene from his carrier mother. Sometimes the change appears for the first time in the child and does not come from the family. The daughters of an affected father will very likely carry the gene. Women who are carriers may have a risk of mild muscle weakness and heart problems. Genetic counselling helps the family understand the risk.
Source: MedlinePlus Genetics: Duchenne and Becker muscular dystrophy · MedlinePlus Medical Encyclopedia: Becker muscular dystrophy · NHS: Muscular dystrophy
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
For all rare diseases: Nadir Hastalıklar Federasyonu
Links checked on October 8, 2026.
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
USAResearch and clinical trials
In the USA, 12 adults with Becker muscular dystrophy took sevasemten, an experimental drug, for 24 months.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
Questions you can ask your doctor
ClinicalTrials.gov lists 4 active interventional studies for this disease. 1 is recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.
Selected records (studies with a site in Türkiye first):
Middle stage: the effect is being tested in a small group · Phase 2 · investigational (experimental)Enrolling by invitationNCT06066580
Non-drug study (device, procedure, care, etc.)RecruitingNCT07415837
Non-drug study (device, procedure, care, etc.)Not yet recruitingNCT07101185
Non-drug study (device, procedure, care, etc.)Enrolling by invitationNCT06363526
See all studies on ClinicalTrials.gov · Joining clinical trials
InternationalResearch and clinical trials
The HIMALAYA study, published in The Lancet Neurology, examined an experimental drug in patients with ALS (amyotrophic lateral sclerosis).
TürkiyeResearch and clinical trials
A multicenter study in Istanbul compared patients with Guillain-Barré syndrome.
USANew treatments and approvals
The US Food and Drug Administration (FDA) approved levacetylleucine for balance and walking problems in ataxia-telangiectasia (A-T).
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:98895 · ICD-11 8C70.0
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.